Navigation Links
Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint
Date:2/12/2008

aclitaxel alone.

About the BO17708 study

BO17708 is an international phase III trial which randomized 736 patients who did not receive previous chemotherapy for their metastatic breast cancer to one of three groups;

-- Avastin 7.5 mg/kg every 3 weeks in combination with docetaxel

-- Avastin 15 mg/kg every 3 weeks in combination with docetaxel

-- docetaxel + placebo as control arm

The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms compared to the control arm. Secondary endpoints for the study included overall survival, response rate, duration of response, quality of life, safety and tolerability.

About Avastin

Data from the comprehensive Avastin cancer clinical development programme have resulted in approvals in advanced colorectal, breast, lung, and kidney cancer:

-- February 2004 (US) and January 2005 (EU) -- first-line treatment in

patients with metastatic colorectal cancer (CRC).

-- June 2006 (US) -- second-line treatment in patients with metastatic

CRC.

-- October 2006 (US) -- first-line treatment in patients with advanced

non-small cell lung cancer (NSCLC).

-- March 2007 (EU) -- first-line treatment in patients with metastatic

breast cancer.

-- April 2007 (Japan) -- treatment in patients with recurrent or advanced

CRC.

-- August 2007 (EU) -- first-line treatment in patients with advanced

NSCLC.

-- December 2007 (EU) -- first-line treatment in patients with advanced

RCC.

-- January 2008 (EU) -- first and later-line treatment in patients with

metastatic CRC in combination with any chemotherapy.

All trademarks used or mentioned in this release are legally protected.

Additional information

To access video clips about Avastin, in broadcast standard, free of charge, please go
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. Second Thoughts about Fluoride, Reports Scientific American
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
8. Immtech Reports Fiscal Second Quarter 2008 Results
9. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
10. Rcadias COR Analyzer Family of Products Receives Second FDA Clearance
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015 Vermillion, Inc. (Nasdaq: ... focused on gynecologic disease, announced today it will ... the market open on Wednesday, March 25, 2015, ... at 8:30am Eastern. Conference Call & Webcast: ... Eastern/5:30am Pacific Domestic: , 800-753-9057International: , 913-981-5571Conference ID: ...
(Date:3/5/2015)... 5, 2015  BioPhotas, Inc., an FDA registered medical ... photo-therapeutic technologies to treat skin, muscle and joint conditions, ... Fi Fund to provide BioPhotas, flagship product, the ... management solutions.  Commenting on the alliance, ... used the Celluma at the Warrior Hope and Care ...
(Date:3/5/2015)... 5, 2015  Medical Diagnostic Laboratories, L.L.C., (MDL), ... complexity, state-of-the-art, automated DNA-based molecular analyses, announces that ... testing which utilizes cutting edge technology, including next- ... approximately 12,000 women are diagnosed with cervical cancer ... Genital Human Papillomaviruses (HPV) are a group of ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3
... 2011 As the biopharmaceutical marketplace has evolved, leading ... to change as well. Specifically, Market Research is shifting ... shaping strategic objectives for key commercial groups. ... increasingly use new and innovative tools such as Webcams ...
... 10, 2011 American Medical Systems® (AMS) (Nasdaq: ... and therapies for male and female pelvic health, today ... of the Elevate® Anterior and Apical Prolapse Repair System. ... quantify, describe and stage pelvic support, was implemented in ...
Cached Medicine Technology:Strategic Role Becoming Critical Part of Market Research Function 2Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS' Elevate Anterior and Apical Prolapse Repair System 2
(Date:3/5/2015)... Battle Creek, Michigan (PRWEB) March 05, 2015 ... celebrates the opportunity to shatter myths about drug and ... Forever Recovery has released a Fact Sheet with information ... substance abuse. Launched in 2010 by the National Institute ... about drugs and alcohol aims to counteract the illusions ...
(Date:3/5/2015)... Anaheim, Calif. (PRWEB) March 05, 2015 ... plant-powered beverages, today announced at Natural Products Expo West ... drinks are now 100 percent soy and dairy free. ... 10.5-ounce single serve bottle and are packed with six ... rice protein that includes fiber, B vitamins and magnesium. ...
(Date:3/5/2015)... Supply & Demand Chain Executive Magazine has officially ... in the supply chain industry, and we are excited ... were included on this year’s list! Russ King and ... to their hard work, their commitment to excellence, and ... client needs and challenges. , Russ and ...
(Date:3/5/2015)... March 05, 2015 As a ... (AAPA) review of Clearstream, LLC ’s products, ... Clearstream’s MediDefense line of products—led by their mPulse ... Affinity Partner Program. , The AAPA—which represents a ... all medical and surgical specialties in the U.S.—advocates ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
Breaking Medicine News(10 mins):Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... University of Jerusalem faculty members have been named winners ... research efforts which have yielded highly successful business applications ... Robert H. Smith Faculty of Agriculture, Food and Environment ... winner of the first prize. Rabinowitch, a former rector ...
... 22 June 2011 Elsevier Middle East announces that ... selected for inclusion in MEDLINE, the premier bibliographic database ... for articles indexed, the indexing terms and the abstract ... ( www.pubmed.gov ). Indexing using the US National Library ...
... lateral sclerosis (ALS) could lose brain function earlier than ... about their care. Physicians need a method to assess ... for extensive neuropsychological tests. Penn State College of ... disease (FTD) deficits in judgment and problem-solving in ALS ...
... Computer algorithms might be useful in identifying sources of ... Writing in the International Journal of Environment and ... is to trace such pollution. Groundwater is a ... urban and rural areas. Although groundwater represents a small ...
... -- Heart damage caused by heavy cocaine use can occur ... Researchers assessed the heart health of 30 long-term cocaine users, ... hours after they last used cocaine. They had been using ... 5.5 grams of cocaine per day. Snorting was the ...
... recent study published in Panminerva Medica reveals ... taken by stable heart failure patients as an adjunct ... blood volume ejected with each beat. As a ... and patients become more physically energetic. Furthermore, blood ...
Cached Medicine News:Health News:Three senior Hebrew University faculty members receive Kaye Awards for innovations 2Health News:Brief exam diagnoses cognitive impairment in ALS patients 2Health News:Tracking groundwater pollution to its source 2Health News:Cocaine-Related Heart Damage May Be 'Silent' 2Health News:Study shows pine bark naturally improves heart function 2Health News:Study shows pine bark naturally improves heart function 3Health News:Study shows pine bark naturally improves heart function 4
This pattern transform your pupils into narrow slits surrounded by eye stopping yellow. Works well with kitty-cat costumes....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Maumenee vitreous aspirating cannula, 18 gauge....
Reusable blunt cannula with luer hub. Cannula length is 32 mm....
Medicine Products: